Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Global Lung Cancer Drugs Market 2019-2025: Recent Drug Approvals and Collaborations & Increasing R&D Spending with Increasing Incidences of Lung Cancer Cases | ||
By: PR Newswire Association LLC. - 18 May 2019 | Back to overview list |
|
DUBLIN, May 17, 2019 /PRNewswire/ -- The "Global Lung Cancer Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025" report has been added to ResearchAndMarkets.com's offering. Global Lung Cancer Drugs Market will grow at a CAGR of 13.6% during the forecast period. The leading global pharmaceutical companies are focusing on product approvals as first-line treatment therapy and combination treatment with chemotherapy, collaborations, and regulatory submission of already matured cancer treatments in the developing countries as a major strategy to increase their revenue. Many of the global players are also focusing on providing home infusion services in the developed markets with secured and safe cold chain logistic infrastructure. This Direct-to-Patient (DTP) strategy is also helping market players to expand their patient volumes and thus the overall revenues globally. The market generates the revenue from the key players operating in this field and some of them include, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Janssen, Amgen, AstraZeneca PLC, Pfizer, Inc., Eli Lilly & Company Ltd, and Novartis AG.
The non-small cell lung cancer segment occupied the largest share in 2018 and is expected to grow at mid-double digit CAGR during the forecast period. The increasing incidence and prevalence of non-small cell lung cancer and rapid industrialization make the segment the fastest growing during the forecast period 2019-2025.
In 2018, the small molecules segment occupied the largest share and biologics is expected to grow at a high CAGR during the forecast period due to increasing adoption of biologics, strong pipeline targeting first-line treatments, and recent product approvals. North America is dominant in the global lung cancer drugs market followed by Europe and Asia Pacific. The significant share of the North America market comes from the US due to the availability of favourable reimbursement policies. Lung Cancer Drugs Market Research Competitive Analysis - The global lung cancer drugs market has massive growth opportunities in both developed and developing regions. Many companies are concentrating on new approvals, collaborations, and development of new drugs to treat lung cancer due to an increase in the incidence of cancer and the need for advanced treatments. For instance, the European Commission has approved brigatinib (Alunbrig) developed by Takeda Pharmaceutical in November 2018 to treat adult patients with ALK-positive non-small cell lung cancer (NSCLC) who were previously treated with crizotinib (Xalkori). FDA approved durvalumab (Imfinzi) developed by AstraZeneca Inc. in February 2018 for the treatment of unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. In addition, other leading vendors are focusing on investing huge on research and development activities to develop new products to obtain a high share in the market.
Key Competitive Facts Increasing incidence of the disease globally, promising drug pipeline, and enormous R&D activities for lung cancer drug development are the major factors driving the market growth. The pipeline of oncology drugs in the clinical development has expanded by 45% over the past 10 years; 87% of the late-stage pipeline is targeted therapies, which include small molecule protein kinase inhibitors and biologic monoclonal antibodies. Market Characteristics Global Lung Cancer Drugs Market Dynamics Drivers
Opportunities
Restraints
Vendor Profiles
Companies to Watch For
For more information about this report visit https://www.researchandmarkets.com/r/blo356 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. Media Contact: Research and Markets SOURCE Research and Markets |
||
|
||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |